Covered, compounding — a low yield on a fast grower. A 0.54% yield that is not the point: $1.73 a quarter on a 22.5% payout, raised 15.3% from $1.50, against Q2 2026 revenue up 48% to $23.0 billion on Mounjaro and Zepbound volume. The income compounds because earnings do — the yield stays low because the price has run, up about 54% over the past year.
Key risk: Concentration plus price — Mounjaro and Zepbound drove $14.9 billion of Q2’s $23.0 billion revenue, and realized prices fell 13% in the quarter; a patent, pricing, or competition shock hits earnings and the multiple together.
Changes if: The payout pushes well past 22.5% on falling earnings, or dividend growth stops. Price alone does not change this verdict.
- ✓Payout-coverage check: 22.5% trailing payout ratio — $6.92 indicated against earnings that leave most of each dollar retained for growth and pipeline spending.
- ✓Yield check: 0.54% indicated — $1.73/qtr × 4 at the $1,273.46 close on Oct. 23, 2026. The yield is small because the price is high, not because coverage is thin.
- ✓Dividend growth check: 11 consecutive years of increases; the latest raise lifted the quarterly dividend 15.3%, from $1.50 to $1.73, in early 2026.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.